Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status

Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer’s diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer’s pathology in the brain. A total of 1189 participants with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xue-Ning Shen, Yu-Yuan Huang, Shi-Dong Chen, Yu Guo, Lan Tan, Qiang Dong, Jin-Tai Yu, Alzheimer’s Disease Neuroimaging Initiative
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/ed93184db7324f0790dfe024c06363af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed93184db7324f0790dfe024c06363af
record_format	dspace
spelling	oai:doaj.org-article:ed93184db7324f0790dfe024c06363af2021-11-14T12:11:31ZPlasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status10.1038/s41398-021-01709-92158-3188https://doaj.org/article/ed93184db7324f0790dfe024c06363af2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41398-021-01709-9https://doaj.org/toc/2158-3188Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer’s diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer’s pathology in the brain. A total of 1189 participants with plasma p-tau181 and PET data of amyloid, tau or FDG PET were included from ADNI. Cross-sectional relationships of plasma p-tau181 with PET biomarkers were tested. Longitudinally, we further investigated whether different p-tau181 levels at baseline predicted different progression of Alzheimer’s pathological changes in the brain. We found plasma p-tau181 significantly correlated with brain amyloid (Spearman ρ = 0.45, P < 0.0001), tau (0.25, P = 0.0003), and FDG PET uptakes (−0.37, P < 0.0001), and increased along the Alzheimer’s continuum. Individually, plasma p-tau181 could detect abnormal amyloid, tau pathologies and hypometabolism in the brain, similar with or even better than clinical indicators. The diagnostic accuracy of plasma p-tau181 elevated significantly when combined with clinical information (AUC = 0.814 for amyloid PET, 0.773 for tau PET, and 0.708 for FDG PET). Relationships of plasma p-tau181 with brain pathologies were partly or entirely mediated by the corresponding CSF biomarkers. Besides, individuals with abnormal plasma p-tau181 level (>18.85 pg/ml) at baseline had a higher risk of pathological progression in brain amyloid (HR: 2.32, 95%CI 1.32–4.08) and FDG PET (3.21, 95%CI 2.06–5.01) status. Plasma p-tau181 may be a sensitive screening test for detecting brain pathologies, and serve as a predictive biomarker for Alzheimer’s pathophysiology.Xue-Ning ShenYu-Yuan HuangShi-Dong ChenYu GuoLan TanQiang DongJin-Tai YuAlzheimer’s Disease Neuroimaging InitiativeNature Publishing GrouparticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENTranslational Psychiatry, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Xue-Ning Shen Yu-Yuan Huang Shi-Dong Chen Yu Guo Lan Tan Qiang Dong Jin-Tai Yu Alzheimer’s Disease Neuroimaging Initiative Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
description	Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer’s diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer’s pathology in the brain. A total of 1189 participants with plasma p-tau181 and PET data of amyloid, tau or FDG PET were included from ADNI. Cross-sectional relationships of plasma p-tau181 with PET biomarkers were tested. Longitudinally, we further investigated whether different p-tau181 levels at baseline predicted different progression of Alzheimer’s pathological changes in the brain. We found plasma p-tau181 significantly correlated with brain amyloid (Spearman ρ = 0.45, P < 0.0001), tau (0.25, P = 0.0003), and FDG PET uptakes (−0.37, P < 0.0001), and increased along the Alzheimer’s continuum. Individually, plasma p-tau181 could detect abnormal amyloid, tau pathologies and hypometabolism in the brain, similar with or even better than clinical indicators. The diagnostic accuracy of plasma p-tau181 elevated significantly when combined with clinical information (AUC = 0.814 for amyloid PET, 0.773 for tau PET, and 0.708 for FDG PET). Relationships of plasma p-tau181 with brain pathologies were partly or entirely mediated by the corresponding CSF biomarkers. Besides, individuals with abnormal plasma p-tau181 level (>18.85 pg/ml) at baseline had a higher risk of pathological progression in brain amyloid (HR: 2.32, 95%CI 1.32–4.08) and FDG PET (3.21, 95%CI 2.06–5.01) status. Plasma p-tau181 may be a sensitive screening test for detecting brain pathologies, and serve as a predictive biomarker for Alzheimer’s pathophysiology.
format	article
author	Xue-Ning Shen Yu-Yuan Huang Shi-Dong Chen Yu Guo Lan Tan Qiang Dong Jin-Tai Yu Alzheimer’s Disease Neuroimaging Initiative
author_facet	Xue-Ning Shen Yu-Yuan Huang Shi-Dong Chen Yu Guo Lan Tan Qiang Dong Jin-Tai Yu Alzheimer’s Disease Neuroimaging Initiative
author_sort	Xue-Ning Shen
title	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
title_short	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
title_full	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
title_fullStr	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
title_full_unstemmed	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
title_sort	plasma phosphorylated-tau181 as a predictive biomarker for alzheimer’s amyloid, tau and fdg pet status
publisher	Nature Publishing Group
publishDate	2021
url	https://doaj.org/article/ed93184db7324f0790dfe024c06363af
work_keys_str_mv	AT xueningshen plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT yuyuanhuang plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT shidongchen plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT yuguo plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT lantan plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT qiangdong plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT jintaiyu plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus AT alzheimersdiseaseneuroimaginginitiative plasmaphosphorylatedtau181asapredictivebiomarkerforalzheimersamyloidtauandfdgpetstatus
_version_	1718429440038404096

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status

Ejemplares similares